Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Investigating the role of the Ste20-like kinase SLK in breast cancer metastasis in vivo
FY 2017-18
Summary
HER2 is an oncogene that promotes the cell’s proliferation and migration. It is overexpressed in breast cancer where it is associated to a poor prognosis and low survival rate. If this cancer remains un-noticed, or becomes resistant it will progress into a metastatic cancer. Once these cancers become metastatic the survival rate drops from 86% to 22%. For a cancer to become metastatic is must undergo a process known as EMT, which is where the cells proliferate less and become more invasive. It has previously been shown that SLK functions downstream of HER2. We have also shown that a SLK knockdown in normal breast epithelial cells caused a delay in EMT. This is why we propose a SLK deletion in a HER+ breast cancer will cause a delay in EMT which will affect the tumours metastatic potential. We were able to generate HER2+ tumour cells that are SLK positive and negative. These cells will be injected into mice to determine their metastatic properties. Quantification of these metastasizes will be done through HER2 histochemistry. Surgical resections of tumours will also be done to. Following surgery mice will be left for 4 weeks and then sacrificed to allow for HER2 histochemistry once again on the bone and lungs. Finally we will treat will SLK specific inhibitors following the surgical resection of the tumour to identify whether these inhibitors function properly and metastasis is slowed. In total we will show how SLK is able to inhibit metastasis of HER2+ breast tumours.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
403464
Name
Abou-Hamad John
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of the Ste20-like kinase SLK in breast cancer metastasis in vivo
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Emt; Metastasis; Slk
Abstract
HER2 is an oncogene that promotes the cell’s proliferation and migration. It is overexpressed in breast cancer where it is associated to a poor prognosis and low survival rate. If this cancer remains un-noticed, or becomes resistant it will progress into a metastatic cancer. Once these cancers become metastatic the survival rate drops from 86% to 22%. For a cancer to become metastatic is must undergo a process known as EMT, which is where the cells proliferate less and become more invasive. It has previously been shown that SLK functions downstream of HER2. We have also shown that a SLK knockdown in normal breast epithelial cells caused a delay in EMT. This is why we propose a SLK deletion in a HER+ breast cancer will cause a delay in EMT which will affect the tumours metastatic potential. We were able to generate HER2+ tumour cells that are SLK positive and negative. These cells will be injected into mice to determine their metastatic properties. Quantification of these metastasizes will be done through HER2 histochemistry. Surgical resections of tumours will also be done to. Following surgery mice will be left for 4 weeks and then sacrificed to allow for HER2 histochemistry once again on the bone and lungs. Finally we will treat will SLK specific inhibitors following the surgical resection of the tumour to identify whether these inhibitors function properly and metastasis is slowed. In total we will show how SLK is able to inhibit metastasis of HER2+ breast tumours.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Abou-Hamad, John
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~